China’s Sinovac Doubles CoronaVac Annual Production Capacity to 2 Million Doses

The Chinese drug company Sinovac Biotech has doubled its annual capacity for the COVID-19 vaccine to 2 billion doses, according to Reuters.

• The additional capacity comes from its third production plant, which is ready and has already started manufacturing procedures for bulk vaccine ingredients.
• A company spokesperson said the third facility is located in Beijing. It has already started cultivating cells where the coronavirus will be grown through a relatively long procedure.
• The pharmaceutical firm did not provide a timeline for the production of 2 billion doses of the vaccine.
• Over 200 million doses of Sinovac’s CoronaVac vaccine have been delivered globally, up from 160 million doses reported on March 22. Over 100 million doses have been administered across the globe.